{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:53:38Z","timestamp":1785779618591,"version":"3.56.0"},"reference-count":33,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Duvelisib, a potent \u03b4\u2010 and \u03b3\u2010PI3K inhibitor, is a potential therapeutic for hematologic malignancies. Rituximab and bendamustine have demonstrated activity in non\u2010Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Combining duvelisib with either rituximab alone or rituximab and bendamustine may improve response rates and remission durability. We conducted this Phase one study in relapsed\/refractory NHL and CLL patients. During expansion, each arm enrolled to disease\u2010specific cohorts to assess efficacy. Arm one received rituximab 375\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    IV weekly for two 4\u2010week\u2009cycles plus duvelisib until progression\/intolerance. Arm two received rituximab 375\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    IV Day one, bendamustine 90\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    IV (NHL patients) or 70\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    IV (CLL patients) Days one\u2010two for six cycles, plus duvelisib until progression\/intolerance. Duvelisib doses of 50\u2009mg and 75\u2009mg BID were tested during dose escalation. Forty\u2010six patients (27 NHL, 19 CLL) were treated. The adverse events of the drug combinations were consistent with single agent toxicities. The most common AEs were neutropenia (47.7%), fatigue (41.3%), and rash (41.3%). A duvelisib expansion dose of 25\u2009mg BID was chosen based on the monotherapy phase one study, IPI\u2010145\u201002, which confirmed that dose for further clinical development. Overall response rate was 71.8%. Median progression\u2010free survival was 13.7 months. Median overall survival has not been reached, but 30\u2010month overall survival probability was 62%. Duvelisib combined with rituximab, or bendamustine and rituximab did not appear to increase toxicities beyond the known safety profile of the individual agents. Further study is needed to determine if these combinations improve efficacy.\n                  <\/jats:p>","DOI":"10.1002\/ajh.25634","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T05:20:21Z","timestamp":1567747221000},"page":"1325-1334","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Combination trial of duvelisib (IPI\u2010145) with rituximab or bendamustine\/rituximab in patients with non\u2010Hodgkin lymphoma or chronic lymphocytic leukemia"],"prefix":"10.1002","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-290X","authenticated-orcid":false,"given":"Ian W.","family":"Flinn","sequence":"first","affiliation":[{"name":"Sarah Cannon Research Institute  Nashville Tennessee"},{"name":"Tennessee Oncology PLLC  Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-9095","authenticated-orcid":false,"given":"Mohamad A.","family":"Cherry","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute  Nashville Tennessee"},{"name":"Department of Hematology and Oncology Stephenson Cancer Center  Oklahoma City Oklahoma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Maris","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute  Nashville Tennessee"},{"name":"Colorado Blood Cancer Institute  Denver Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Matous","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute  Nashville Tennessee"},{"name":"Colorado Blood Cancer Institute  Denver Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute  Nashville Tennessee"},{"name":"Tennessee Oncology PLLC  Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute  Nashville Tennessee"},{"name":"Florida Cancer Specialists  Sarasota Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results Program.https:\/\/seer.cancer.gov https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed February 22 2019."},{"key":"e_1_2_7_3_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology for Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Version 3 February 21 2019.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf."},{"key":"e_1_2_7_4_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology for B\u2010cell Lymphomas. Version 1 November 30 2019.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"key":"e_1_2_7_5_1","unstructured":"Duvelisib Prescribing Information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211155s000lbl.pdf. Accessed February 22 2019."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850461"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00915"},{"key":"e_1_2_7_8_1","first-page":"882","article-title":"PI3K\u2010\u03b4 and PI3K\u2010\u03b3 inhibition by IPI\u2010145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models","volume":"1851","author":"Winkler DG","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.087171"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.02.004"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9289"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.16"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.105"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1312338"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386763"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535047"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041720"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-786566"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25228"},{"key":"e_1_2_7_20_1","unstructured":"Guidance for Industry Drug\u2010Induced Liver Injury: Premarketing Clinical Evaluation.https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM174090.pdf. Accessed February 22 2019."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_22_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. US Department of Health and Human Services;2010."},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2424"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2016.0022"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1735.1735"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30082-2"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119123"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4648"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.10.99"},{"key":"e_1_2_7_34_1","unstructured":"International Council for Harmonisation Guidelines on GoodClinical Practice.https:\/\/ichgcp.net. Accessed September 16 2019."}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25634","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25634","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25634","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:12:55Z","timestamp":1785777175000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1002\/ajh.25634"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25634","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,4]]},"assertion":[{"value":"2019-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}